Shang Haotian, Chen Yanan, Wang Qiulu, Yang Yongliang, Zhang Jingyu
Department of Oncology, Clinical College of Second People's Hospital of Lianyungang, Bengbu Medical College, Lianyungang, People's Republic of China.
J Inflamm Res. 2024 Mar 29;17:2009-2021. doi: 10.2147/JIR.S450669. eCollection 2024.
This study aimed to investigate the relationship between peripheral blood indices and the efficacy and prognosis of advanced esophageal squamous cell carcinoma (ESCC) patients treated with camrelizumab.
We retrospectively analyzed 64 patients who received camrelizumab for advanced ESCC at the Second People's Hospital of Lianyungang City between July 2020 and June 2022. The study included examination of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the systemic inflammation index (SII), the lymph-to-monocytes ratio (LMR), the absolute lymphocyte count (ALC), and lactate dehydrogenase (LDH). We used multivariate logistic regression analysis to explore the link existing between peripheral blood and the efficacy of treatment. Determination of potential prognostic factors for Progression-free survival (PFS) and Overall survival (OS) using Cox regression analysis. The nomogram model was developed based on the results of the Cox multivariate analysis. Patients were divided into three groups according to the reduction in LDH and LDL levels before treatment, and the Kaplan-Meier survival curves for the three groups were compared and ROC curves for LDH combined with PLR were plotted.
Lower LDH (OR=6.237, 95% CI: 1.625-23.944) were independently associated with disease control rates(DCR). LDH was independently correlated with PFS (HR: 0.227 95% CI: 0.099-0.517). LDH and PLR were independently linked to OS. The C index of the nomogram model is 0.819, indicating good predictive performance. Kaplan-Meier Survival Curve suggested better OS in patients with reduced pretreatment LDH and PLR. The area under the ROC curve showed that the LDH index combined with the PLR index predicts patient survival better than the index alone.
LDH combined with PLR predicted prognosis in patients with ESCC treated with camrelizumab.
本研究旨在探讨外周血指标与接受卡瑞利珠单抗治疗的晚期食管鳞状细胞癌（ESCC）患者疗效及预后的关系。
我们回顾性分析了2020年7月至2022年6月期间在连云港市第二人民医院接受卡瑞利珠单抗治疗的64例晚期ESCC患者。该研究包括检测中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、全身炎症指数（SII）、淋巴细胞与单核细胞比值（LMR）、绝对淋巴细胞计数（ALC）和乳酸脱氢酶（LDH）。我们采用多因素逻辑回归分析来探究外周血与治疗疗效之间的联系。使用Cox回归分析确定无进展生存期（PFS）和总生存期（OS）的潜在预后因素。基于Cox多因素分析结果构建列线图模型。根据治疗前LDH和LDL水平的降低情况将患者分为三组，并比较三组的Kaplan-Meier生存曲线，绘制LDH联合PLR的ROC曲线。
较低的LDH（OR=6.237，95%CI：1.625-23.944）与疾病控制率（DCR）独立相关。LDH与PFS独立相关（HR：0.227，95%CI：0.099-0.517）。LDH和PLR与OS独立相关。列线图模型的C指数为0.819，表明预测性能良好。Kaplan-Meier生存曲线表明，治疗前LDH和PLR降低的患者OS更好。ROC曲线下面积显示，LDH指数联合PLR指数预测患者生存情况优于单独使用该指数。
LDH联合PLR可预测接受卡瑞利珠单抗治疗的ESCC患者的预后。
